Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
An update from Marvel Biosciences Corp ( (TSE:MRVL) ) is now available.
Marvel Biosciences Corp. announced that the Chinese patent office has issued a notice of allowance for its lead compound MB-204, a novel fluorinated derivative of the Parkinson’s drug Istradefylline, marking the first worldwide allowance for this family of patents. This development underscores Marvel’s progress in securing intellectual property protection as it prepares to advance MB-204 into clinical trials, potentially strengthening its position in the pharmaceutical industry and benefiting stakeholders interested in neurological disease treatments.
More about Marvel Biosciences Corp
Marvel Biosciences Corp., based in Calgary, is a pre-clinical stage pharmaceutical development biotechnology company that employs a ‘drug redevelopment’ approach to create synthetic chemical derivatives of approved drugs for new disease indications. The company focuses on neurological diseases like depression, Alzheimer’s, and autism, as well as non-neurological conditions such as cancer and non-alcoholic steatohepatitis.
YTD Price Performance: 6.67%
Average Trading Volume: 58,043
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: C$6.72M
Find detailed analytics on MRVL stock on TipRanks’ Stock Analysis page.
